Compare NUTX & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | BWAY |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | Israel |
| Employees | 944 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.4M | 450.8M |
| IPO Year | 2009 | N/A |
| Metric | NUTX | BWAY |
|---|---|---|
| Price | $93.81 | $12.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $252.50 | $13.25 |
| AVG Volume (30 Days) | ★ 171.6K | 160.1K |
| Earning Date | 03-05-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.93 | N/A |
| EPS | ★ 10.48 | N/A |
| Revenue | ★ $875,257,000.00 | N/A |
| Revenue This Year | $8.28 | $301.23 |
| Revenue Next Year | $1.96 | $24.33 |
| P/E Ratio | ★ $9.05 | $81.98 |
| Revenue Growth | ★ 82.36 | N/A |
| 52 Week Low | $45.88 | $7.84 |
| 52 Week High | $193.07 | $26.63 |
| Indicator | NUTX | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 29.70 |
| Support Level | $81.70 | $11.55 |
| Resistance Level | $110.29 | $13.63 |
| Average True Range (ATR) | 6.81 | 0.72 |
| MACD | 1.50 | 0.19 |
| Stochastic Oscillator | 36.56 | 17.62 |
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.